Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023387872> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W2023387872 endingPage "81" @default.
- W2023387872 startingPage "80" @default.
- W2023387872 abstract "En la embarazada expuesta a tuberculosis (TB) no se recomienda profilaxis primaria con isoniazida salvo en gestantes inmunodeprimidas, con enfermedades crónicas o factores de riesgo obstétrico y antecedente de contacto íntimo mantenido con un enfermo bacilífero. En la infección tuberculosa latente (ITBL) se iniciará profilaxis con isoniazida si existe contacto reciente con TB o factores de riesgo de progresión a TB activa. En caso contrario, se retrasará hasta al menos 3 semanas después del parto. El tratamiento de la enfermedad tuberculosa es el mismo que fuera de la gestación. Los recién nacidos de madres con historia gestacional de TB diseminada o extrapulmonar, con TB activa en el parto o con contacto TB posnatal conocido, asintomáticos y con pruebas diagnósticas negativas, deben recibir profilaxis primaria con isoniazida durante al menos 12 semanas. Transcurrido ese tiempo se repiten los test diagnósticos, y si son negativos, se interrumpe la profilaxis. En la ITBL, se administrará isoniazida durante 9 meses. En la enfermedad tuberculosa, el tratamiento es el mismo que en el niño mayor pero mantenido al menos 9 meses. Se recomienda aislamiento respiratorio en la TB congénita y en la TB posnatal con baciloscopia positiva en jugo gástrico o aspirado bronquial. La separación madre-hijo solo está indicada en madres que han recibido tratamiento durante menos de 2 semanas, presentan baciloscopia positiva o tienen TB resistente. La lactancia materna no está contraindicada y en las situaciones de separación la madre puede extraerse la leche para que sea administrada en biberón al recién nacido.In pregnant women who have been exposed to tuberculosis (TB), primary isoniazid prophylaxis is only recommended in cases of immunosuppression, chronic medical conditions or obstetric risk factors, and close and sustained contact with a patient with infectious TB. Isoniazid prophylaxis for latent tuberculosis infection (LTBI) is recommended in women who have close contact with an infectious TB patient or have risk factors for progression to active disease. Otherwise, it should be delayed until at least three weeks after delivery. Treatment of TB disease during pregnancy is the same as for the general adult population. Infants born to mothers with disseminated or extrapulmonary TB in pregnancy, with active TB at delivery, or with postnatal exposure to TB, should undergo a complete diagnostic evaluation. Primary isoniazid prophylaxis for at least 12 weeks is recommended for those with negative diagnostic tests and no evidence of disease. Repeated negative diagnostic tests are mandatory before interrupting prophylaxis. Isoniazid for 9 months is recommended in LTBI. Treatment of neonatal TB disease is similar to that of older children, but should be maintained for at least 9 months. Respiratory isolation is recommended in congenital TB, and in postnatal TB with positive gastric or bronchial aspirate acid-fast smears. Separation of mother and infant is only necessary when the mother has received treatment for less than 2 weeks, is sputum smear-positive, or has drug-resistant TB. Breastfeeding is not contraindicated, and in case of mother-infant separation expressed breast milk feeding is recommended." @default.
- W2023387872 created "2016-06-24" @default.
- W2023387872 creator A5011683882 @default.
- W2023387872 creator A5051518124 @default.
- W2023387872 creator A5065128040 @default.
- W2023387872 creator A5021829947 @default.
- W2023387872 date "2005-01-01" @default.
- W2023387872 modified "2023-10-18" @default.
- W2023387872 title "Tratamiento con bomba de insulina en un niño de 21 meses" @default.
- W2023387872 cites W2035450251 @default.
- W2023387872 cites W2050798815 @default.
- W2023387872 cites W2065739588 @default.
- W2023387872 cites W2116415328 @default.
- W2023387872 cites W2140147198 @default.
- W2023387872 cites W2156954262 @default.
- W2023387872 doi "https://doi.org/10.1157/13070189" @default.
- W2023387872 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15642249" @default.
- W2023387872 hasPublicationYear "2005" @default.
- W2023387872 type Work @default.
- W2023387872 sameAs 2023387872 @default.
- W2023387872 citedByCount "0" @default.
- W2023387872 crossrefType "journal-article" @default.
- W2023387872 hasAuthorship W2023387872A5011683882 @default.
- W2023387872 hasAuthorship W2023387872A5021829947 @default.
- W2023387872 hasAuthorship W2023387872A5051518124 @default.
- W2023387872 hasAuthorship W2023387872A5065128040 @default.
- W2023387872 hasConcept C142362112 @default.
- W2023387872 hasConcept C15708023 @default.
- W2023387872 hasConcept C29456083 @default.
- W2023387872 hasConcept C71924100 @default.
- W2023387872 hasConceptScore W2023387872C142362112 @default.
- W2023387872 hasConceptScore W2023387872C15708023 @default.
- W2023387872 hasConceptScore W2023387872C29456083 @default.
- W2023387872 hasConceptScore W2023387872C71924100 @default.
- W2023387872 hasIssue "1" @default.
- W2023387872 hasLocation W20233878721 @default.
- W2023387872 hasLocation W20233878722 @default.
- W2023387872 hasOpenAccess W2023387872 @default.
- W2023387872 hasPrimaryLocation W20233878721 @default.
- W2023387872 hasRelatedWork W1506200166 @default.
- W2023387872 hasRelatedWork W1995515455 @default.
- W2023387872 hasRelatedWork W2048182022 @default.
- W2023387872 hasRelatedWork W2080531066 @default.
- W2023387872 hasRelatedWork W2604872355 @default.
- W2023387872 hasRelatedWork W2748952813 @default.
- W2023387872 hasRelatedWork W2899084033 @default.
- W2023387872 hasRelatedWork W3031052312 @default.
- W2023387872 hasRelatedWork W3032375762 @default.
- W2023387872 hasRelatedWork W3108674512 @default.
- W2023387872 hasVolume "62" @default.
- W2023387872 isParatext "false" @default.
- W2023387872 isRetracted "false" @default.
- W2023387872 magId "2023387872" @default.
- W2023387872 workType "article" @default.